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Viral resistanceaviviruses in cell culture. At 1.2-μM concentration, lycorine reduced viral titers of
West Nile (WNV), dengue, and yellow fever viruses by 102- to 104-fold. However, the compound did not
inhibit an alphavirus (Western equine encephalitis virus) or a rhabdovirus (vesicular stomatitis virus),
indicating a selective antiviral spectrum. The compound exerts its antiviral activity mainly through
suppression of viral RNA replication. A Val→Met substitution at the 9th amino acid position of the viral 2K
peptide (spanning the endoplasmic reticulum membrane between NS4A and NS4B proteins) confers WNV
resistance to lycorine, through enhancement of viral RNA replication. Initial chemistry synthesis
demonstrated that modiﬁcations of the two hydroxyl groups of lycorine can increase the compound's
potency, while reducing its cytotoxicity. Taken together, the results have established lycorine as a ﬂavivirus
inhibitor for antiviral development. The lycorine-resistance results demonstrate a direct role of the 2K
peptide in ﬂavivirus RNA synthesis.
© 2008 Elsevier Inc. All rights reserved.IntroductionThe family Flaviviridae consists of three genera, the ﬂaviviruses,
the pestiviruses, and the hepatitis C viruses. Many members of the
genus Flavivirus are arthropod-borne human pathogens, including
four serotypes of dengue virus (DENV), West Nile virus (WNV),
Japanese encephalitis virus (JEV), yellow fever virus (YFV), and tick-
borne encephalitis virus (TBEV) (Gubler et al., 2007). More than
50 million, 200,000, and 50,000 human cases were reported annually
for DENV, YFV, and JEV infections, respectively (Gubler et al., 2007).
Since the initial outbreak of WNV in New York in 1999, the virus has
caused thousands of human cases of infections each year and has
spread throughout North America (Kramer et al., 2007). No effective
antiviral therapy has been approved for the treatment of ﬂavivirus
infections. Human vaccines are currently available only for JEV, YFV,
and TBEV. It has been well recognized that development of a vaccine
for DENV is particularly challenging, because of the need to
simultaneously immunize against all four DENV serotypes. Therefore,
development of therapeutics is the priority for intervention in
ﬂavivirus infections.olis Road, #05-01 Chromos,
).
l rights reserved.The ﬂavivirus genome is a plus-sense, single-stranded RNA of
about 11,000 nucleotides (Lindenbach et al., 2007). The genomic RNA
consists of a 5′ untranslated region (UTR), a single open reading frame
(ORF), and a 3′UTR. The single ORF encodes a long polyprotein that is
co-translationally and post-translationally processed by viral and host
proteases into ten mature viral proteins. The N-terminus of the
polyprotein contains three structural proteins: capsid (C), premem-
brane (prM/M), and envelope (E). The C-terminus of the polyprotein
contains seven nonstructural (NS) proteins: NS1, NS2A, NS2B, NS3,
NS4A, NS4B, and NS5. Complete cleavage of the polyprotein generates
a 2K peptide between NS4A and NS4B. The 2K peptide spans the
membrane of endoplasmic reticulum (ER). Two viral proteins have
enzymatic activities. NS3 functions as a protease (with NS2B as a
cofactor), a nucleotide triphosphatase, an RNA triphosphatase, and a
helicase (Falgout, Miller, and Lai, 1993; Li et al., 1999; Warrener et al.,
1993; Wengler and Wengler, 1991). NS5 acts as a methyltransferase
(MTase) and an RNA-dependent-RNA polymerase (RdRp) (Ackermann
and Padmanabhan, 2001; Egloff et al., 2002; Guyatt et al., 2001; Ray et
al., 2006; Tan et al., 1996). Besides functioning in replication, ﬂaviviral
NS proteins play roles in virion assembly (Jones et al., 2005;
Kummerer and Rice, 2002; Leung et al., 2001; Liu et al., 2003) and
evasion of host innate immune responses (Best et al., 2005; Guo et al.,
2005; Liu et al., 2005; Munoz-Jordan et al., 2005; Munoz-Jordan et al.,
2003). Upon viral entry and nucleocapsid uncoating, the genomic RNA
Fig. 1. Identiﬁcation of lycorine as an inhibitor of WNV and DENV-1 VLP infections. (A)
Structure of lycorine. The carbon positions of the lycorine molecule are numbered. (B)
Production of ﬂavivirus VLPs. Flavivirus VLPs were prepared by sequential transfection
of BHK-21 cells with a luciferase-reporting replicon (Flavi-Rluc2A-Rep) and an SFV
vector expressing ﬂavivirus structural proteins (SFV-Flavi-CprME). See Materials and
methods for details. (C) Inhibition of WNV and DENV-1 VLP infections by lycorine. Vero
cells were infected with WNV (1 FFU/cell) or DENV-1 (0.01 FFU/cell) VLPs in the
presence of 1.5 μM lycorine. Luciferase activities were measured at 24 h post-infection.
Average results of three independent experiments are shown.
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membrane to form the replication complexes (Lindenbach et al.,
2007). The molecular details of individual NS proteins and their roles
in ﬂavivirus replication remain to be characterized.
Lycorine is an alkaloid compound found in several plants, such
as daffodil (Narcissus pseudonarcissus) and bush lily (Clivia miniata).
A number of biological activities have been reported for lycorine,
including inhibition of protein and DNA synthesis (Chattopadhyay
et al., 1984), cell growth and division (De Leo et al., 1973), and anti-
leukemia effect (Liu et al., 2004, 2007). In addition, the compound
has been shown to inhibit poliovirus (Ieven et al., 1982), Severe
Acute Respiratory Syndrome-associated coronavirus (SARS-CoV) (Li
et al., 2005), herpes simplex virus (type 1) (Renard-Nozaki et al.,
1989), and vaccinia virus (Zhou et al., 2003).
In this paper, we report that lycorine inhibits ﬂaviviruses with a
selective antiviral spectrum. Mode-of-action analysis indicates that
lycorine inhibits ﬂaviviruses mainly through suppression of viral RNA
synthesis. Structural modiﬁcations of the lycorine compound
increased its potency while decreasing its cytotoxicity, indicating the
potential for the compound's therapeutic development. Furthermore,
we found that a single-amino acid substitution in WNV 2K peptide
confers resistance to lycorine, partially through enhancement of viral
RNA synthesis, thus revealing a direct role of the 2K peptide in
ﬂavivirus RNA replication.
Results
Identiﬁcation of lycorine as an inhibitor of WNV and DENV-1
Lycorine (Fig. 1A) has been reported to have antiviral activities (See
Introduction). To test whether lycorine inhibits ﬂaviviruses, we
initially screened the compound using a viral-like particle (VLP)-
based infection assay. As depicted in Fig. 1B, VLPs of WNV and DENV-1
were prepared by trans-supply viral structural proteins (CprME;
through an alphavirus Semliki Forest virus [SFV] expression vector) to
package corresponding replicon RNAs containing a luciferase reporter
(Rluc2A-Rep). The titers of the VLPs were estimated to be 2.5×106 and
2.4×103 FFU/ml for WNV and DENV-1, respectively. Vero cells were
infected with 1 FFU/cell of WNV VLP or with 0.01 FFU/cell of DENV-1
VLP (due to the low titer of DENV-1 VLP). The infected cells were
treated with 1.5 μM lycorine or were mock-treated with 1% DMSO. At
24 h post-infection (p.i.), lycorine reduced the luciferase signals by
1400- and 1200-fold in the WNV and DENV-1 VLP-infected cells,
respectively (Fig. 1C). Higher concentrations of lycorine were also
tested; however, due to cytotoxicity, these results are not presented
(see next section). The results indicate that lycorine inhibits WNV and
DENV-1.
Inhibition of an epidemic strain of WNV at noncytotoxic concentrations
We performed an MTT assay to determine the cytotoxicity of
lycorine in order to exclude the possibility that the above-described
antiviral activity was due to compound-mediated cytotoxicity (Fig.
2A). Vero cells were incubated with various concentrations of lycorine
for 48 h; cell viability was indicated by cellular metabolism of MTT
tetrazolium salt. The CC50 (50% cytotoxic concentration) value of the
compound was estimated to be 24 μM. At 1.5 μM, cell viability was
N90%. Therefore, all following experimentswere performed at b1.5 μM
of lycorine.
Next,we assayed the antiviral activity of lycorine using an authentic
WNV infection assay. Vero cells were infected with an epidemic strain
of WNV (0.1 MOI). The infections were treated with various
concentrations of the compound, and assayed for viral yields in culture
medium at 42 h p.i. (Fig. 2B). The compound suppressed viral titer in a
dose-responsive manner. At 1.2 μM, the compound reduced the viral
titer by 910-fold. The EC50 (50% effective concentration) value wasestimated to be 0.23 μM. The results demonstrate that lycorine inhibits
WNV at noncytotoxic concentrations.
Selective antiviral spectrum
To examine the antiviral spectrum of lycorine, we performed viral
titer reduction assays using other ﬂaviviruses (DENV-2 and YFV), a
plus-strand RNA alphavirus (Western equine encephalitis virus,
WEEV), and a negative-strand RNA rhabdovirus (vesicular stomatitis
virus, VSV). Lycorine inhibited both DENV-2 and YFV (Fig. 3). At 1.2 μM,
the compound reduced viral titers of DENV-2 and YFV by 1.1×104- and
98-fold, respectively. In contrast, the compound suppressed titers of
neither WEEV nor VSV at the tested concentrations. The latter results
further suggest that lycorine at 1.2 μM is not cytotoxic. Overall, the
results indicate that the antiviral spectrum of the compound is
selective for ﬂaviviruses.
Inhibitory step(s) of viral infection
Given that lycorine inhibits VLP-mediated infection (Fig. 1C), the
compound could block steps of viral entry and/or replication. To
pinpoint the step(s) of compound inhibition, we tested the compound
in the Vero cell lines containing persistently replicating replicon of
WNVorDENV (Rluc-Neo-Rep; Fig. 4A). Incubation of the Rluc-Neo-Rep
cells with 1.5-μM lycorine for 24 h or 48 h led to reduced luciferase
activities, suggesting that the compound inhibits viral translation and/
or RNA synthesis.
Fig. 2. Cytotoxicity and potency of lycorine against an epidemic strain of WNV. (A)
Cytotoxicity of lycorine in Vero cells. Cytotoxicity was examined by incubation of Vero
cells with the indicated concentrations of lycorine. Cell viability was measured by an
MTT assay, and is presented as a percentage of colorimetric absorbance derived from
the compound-treated cells compared with that from the mock-treated cells (with 1%
DMSO). Average results from three experiments are shown. (B) Inhibition of WNV
infection in cell culture. Vero cells were infected with an epidemic strain of WNV (0.1
MOI). The infected cells were immediately treated with lycorine at the indicated
concentrations. Viral titers in culture ﬂuids at 42 h p.i. were determined by plaque
assays.
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differentiate between inhibition of viral translation and inhibition of
RNA synthesis. Previous studies showed that transfection of BHK-21
cells with the Rluc2A-Rep of WNV or DENV-1 produces two luciferase
peaks, one at 1 to 8 h post-transfection (p.t.), and another at N20 h p.t.;
these respectively represent viral translation and RNA replication (Lo
et al., 2003; Puig-Basagoiti et al., 2006). As shown in Fig. 4B, whereas
lycorine suppressed early luciferase signals (at 2, 4, and 6 h p.t.) by
b30%, it reduced late luciferase signals (at 24, 30 and 48 h p.t.) by
N99%. Taken together, the results suggest that lycorine weakly inhibits
viral translation, but strongly suppresses RNA synthesis.Fig. 3. Antiviral spectrum of lycorine. Viral titer reduction assays were performed for DENV-2
Materials and methods.Time-of-addition analysis
A time-of-addition experiment was performed to further elucidate
themode-of-action of lycorine (Fig. 4C). Vero cellswere synchronously
infected withWNV (Puig-Basagoiti et al., 2006). Lycorine (1.2 μM) was
added to the infected cells at various time points post-infection. Viral
titers in the culture medium were determined at 20 h post-infection.
As controls,1%DMSOwas added to infected cells at 0,12, or 20 h p.i., for
estimation of its effect on viral yield. The results showed that the
inhibitory effect of lycorine on viral titer gradually diminished when
the compoundwas added at time points up to 10 h p.i.; the compound
completely lost its antiviral activity when added after 10 h post-
infection. These results agreewith the transient replicon results, which
indicated that lycorine weakly inhibits viral translation, but strongly
suppresses RNA synthesis.
Lycorine does not inhibit WNV protease, NTPase, MTase, or RdRp activities
To identify potential antiviral target(s),we directly tested lycorine in
our previously established enzyme assays, using recombinant proteins
ofWNV, including protease (withNS2B), NTPase,MTase, andRdRp (Ray
et al., 2006; Wong et al., 2003). None of the enzyme activities were
suppressed by the compound at concentrations up to 100 μM (data not
shown). The results suggest that the compound does not directly target
the enzyme functions of the viral NS3 or NS5 proteins.
Selection and characterization of lycorine-resistant WNV
As an alternative means by which to identify antiviral target(s), we
selected lycorine-resistant WNV by culturing wild-type (WT) virus in
the presence of increasing concentrations of the compound (Fig. 5A).
Three independent selections (I-III) were performed. For each
selection, a total of 12 passages were carried out, with the ﬁrst 6
passages (P1-P6) selected at 0.8 μM lycorine and the last 6 passages
(P7-P12) selected at 1.2 μM lycorine. Viruses from each passage were
assayed for their resistance, through comparison of viral titers from
mock-treated infectionwith viral titers from lycorine-treated infection
(harvested at 42 h p.i.). Fig. 5B shows representative data from such
resistance assays for P1, P3, P6, P9, and P12. Viral resistance gradually
improved from P1 to P10; no further improvement was observed from
P10 to P12 (Fig. 5B and data not shown). We therefore terminated the
selections at P12. Notably, the P12 viruses did not show complete
resistance to lycorine. At 1.2 μM, the compound reduced viral titers of
P12 virus-infected cells by approximately 10-fold. In contrast, the
compound suppressed viral titers of the WT virus-infected cells by
about 1000-fold at the same concentration (Fig. 5B). The results
indicated that the resistance of the P12 viruses increased by
approximately 100-fold over that of the WT. Similar results were
obtained for all three independent selections., YFV,WEEV, and VSV in the presence of various concentrations of lycorine. See details in
Fig. 4. Mechanism of lycorine-mediated inhibition of ﬂaviviruses. (A) Antiviral activities in Vero cells containing Rluc-Neo-Rep of WNV (left) and DENV-1 (right). Vero cells
containing a WNV or DENV-1 replicon (Rluc-Neo-Rep) were treated with lycorine at the indicated concentrations, and were measured for luciferase activities at 24 or 48 h post-
treatment. (B) Analysis of lycorine using transient replicons of WNV (left) and DENV-1 (right). Luciferase replicons (Rluc2A-Rep) of WNV or DENV-1 were electroporated into
BHK-21 cells. The transfected cells were immediately incubated with 1.5 μM lycorine, and were measured for luciferase activities at the indicated time points post-transfection.
Numbers above the lycorine-treated datum points indicate percentages of luciferase signals from the compound-treated transfection compared with those from the mock-treated
transfection (set to 100%). Error bars indicate the standard deviations from three independent experiments. (C) Time-of-addition analysis of lycorine in WNV infection. Vero cells
were infected with WNV at an MOI of 10 at 4°C for 1 h. The infected cells were washed three times with PBS. Lycorine (1.2 μM) was then added to the cells at the indicated time
points post-infection. The supernatants were assayed for viral titers at 20 h post-infection. As controls, 1% DMSO was added to the infected cells at 0, 12 and 20 h p.i. for
estimation of its effect on viral production.
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were compared in agar containing no lycorine (Fig. 5C). Plaques derived
from the P12 viruses were slightly more heterogeneous in size than the
plaques derived from theWTvirus, indicating that the P12 viruseswere
composed of quasispecies. However, the majority of the plaques from
the P12 viruses are similar in size to the plaques derived from the WT
virus. Collectively, the results demonstrated that WNVs partially
resistant to lycorine can be reproducibly selected in cell culture.
Sequencing of lycorine-resistant WNV
The complete genomes of P12 viruses from the three independent
selections were sequenced, to identify potential resistance mutation(s). We performed population sequencing by directly sequencing the
RT-PCR products ampliﬁed from the RNA extracted from the P12
culture supernatants (Fig. 5A). All selections had accumulated a
consensus nucleotide change from G to A at position 6871 (G6871A),
resulting in an amino acid substitution from Val to Met at position 9
(Val9Met) in the 2K peptide. No other mutation was detected from
Selection III. For Selections I and II, two additional, but distinct,
nucleotide mutations were recovered in the E gene: one mutationwas
silent, while the other one led to an amino-acid change (Fig. 6A).
Sequencing chromatograms indicated that the E mutations existed in
mixed populations, as represented by bothWTand mutant nucleotide
peaks at the speciﬁc positions (data not shown). As a negative control,
viruses passaged in 1% DMSO did not give rise to any mutations.
Fig. 5. Selection and characterization of lycorine-resistant WNV. (A) Scheme for selection of lycorine-resistant WNV. Three independent selections were performed. P1 through P6
were selected at 0.8 μM lycorine; P7 through P12 were selected at 1.2 μM. (B) Resistance proﬁle during selection. Viruses from each of the 12 passages were monitored for their
resistance. Vero cells were infected with viruses at an MOI of 0.1 in the presence of 0.8 μM lycorine (P1-P6), 1.2 μM lycorine (P7-P12), or 1% DMSO (as a negative control). At 42 h p.i.,
viral titers in culture ﬂuids were quantiﬁed by plaque assays. Resistance is quantiﬁed by comparison of the viral titers from the lycorine-treated infections with the viral titers from
the mock-treated infections. Results for representative passages from the three selections are shown. (C) Plaque morphologies of WTand lycorine-resistant viruses. Plaque assays for
WT and P12 viruses were performed on Vero cells in the absence of lycorine.
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resistance determinant
We prepared two panels of recombinant viruses, to identify the
lycorine-resistance determinant. The ﬁrst panel of viruses contained
the mutations in the E gene. Each of the four mutations in the E region
was individually engineered into an infectious cDNA clone of WNV.
Transfection of BHK-21 cells with the genome-length RNAs resulted in
four mutant viruses (Fig. 6B): C1161U and U1789C (derived from
Selection I), and A1287C and C1418U (derived from Selection II). The
four mutant viruses exhibited different plaque morphologies: the two
viruses containing the silent mutations (C1161U and A1287C) yielded
plaques similar to those of the WT virus, whereas the mutant viruses
containing amino acid changes in the E protein (C1418U and U1789C)
generated smaller plaques than those of the WT virus. Resistance
assays showed that, after treatment of infected cells (0.1 MOI) with
lycorine (1.2 μM lycorine for 42 h), none of the four mutants yielded
viral titers that were signiﬁcantly higher than the titers of the WT
virus (Fig. 6C). The results indicate that the E mutations are not
responsible for resistance. Notably, the smaller plaques (Fig. 6B) and
the lower titers from mock-treated infections for mutant viruses
U1789C and C1418U (Fig. 6C) suggest that the amino acid changes in
the E gene negatively affect viral replication.
The second panel of viruses was prepared to examine the mutation
G6817A in the 2Kpeptide. The plaquemorphology of G6871Aviruswas
similar to that of the WT virus (Fig. 6B). Remarkably, the G6871A virus
showed a resistance level close to those of the P12 viruses fromall threeselections (Fig. 6C). Sequencing of the G6871A mutant virus indicated
that the engineered mutation was retained without extra changes;
furthermore, the G6871A mutation was retained after passaging the
mutant virus in Vero cells for ﬁve rounds (total 10 days; data not
shown). These results demonstrate that the G6871Amutation in the 2K
peptide is the major determinant for lycorine resistance. Sequence
alignment (Fig. 6D) indicates that the mutated Val at amino-acid
position 9 of the 2K peptide (total of 23 amino acids) is conserved
among themembers of the JEV-serocomplex; and a Val at position 10 is
conserved among themembers of the DENV-serocomplex; whereas no
Val is foundat a similar position in the2Kpeptides frommembers of the
YFV- and TBEV-serocomplexes.
Replication kinetics of WT and 2K-mutant viruses in the presence and
absence of lycorine
We further characterized the G6871A mutation by comparing the
replication kinetics between the WT and mutant (MT) viruses in the
presence and absence of lycorine inhibitor. Vero cells were synchro-
nizely infected with the WT and the G6871A MT viruses, and treated
with or without 1.2 μM lycorine. As expected, the compound inhibited
WT virus more dramatically than it did on the MT virus (Fig. 7A).
Western blotting analysis showed that, at 16 h p.i., no viral proteins
could be detected in cells infected with either WT or mutant viruses
(data not shown). For the MT virus, the expression levels of viral NS1,
NS3, and NS5 increased from 24 to 36 h p.i., but decreased at 48 h p.i.;
the decrease in protein expression at 48 h p.i. was due to cytopathic
Fig. 6. Identiﬁcation of a single-amino acid change in the 2K peptide as a resistance determinant. (A) Summary of mutations identiﬁed from the three selections. Locations of the
nucleotide and/or amino acid changes are indicated. Mixed populations (containing both the WT-nucleotide and the indicated mutant-nucleotide) were found in the E gene from
selections I and II. (B) Plaque morphologies of WT and recombinant C1161U, U1789C, A1287C, C1418U, and G6871A viruses. Plaques were developed in the absence of lycorine. (C)
Resistance analyses of WT virus, three independently selected P12 viruses (from Sel, I, II, and III), and recombinant C1161U, U1789C, A1287C, C1418U, and G6871A viruses. The
resistance assays were performed as described in the legend to Fig. 5B. (D) Alignment of amino-acid sequences of ﬂavivirus 2K peptide. The 23-amino acid sequences of 2K peptide
are aligned for nine ﬂaviviruses. The conserved Val residues in viruses from JEV- and DENV-serocomplexes are shaded in grey. The 2K peptide sequences ofWNV, KUNV, JEV, DENV-1,
DENV-2, DENV-3, DENV-4, YFV and TBEV are derived from GenBank accession numbers AF404756, D00246, AF315119, U88535, M29095, M93130, AY947539, X03700, and AF069066,
respectively.
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suppressed viral protein expression. These results conﬁrm the critical
role of the G6871A mutation in lycorine resistance.
Enhancement of RNA replication by the 2K peptide mutation
To further validate the contribution of the G6871A change to
resistance, we engineered the mutation into a reporting replicon
(Rluc2A-Rep) of WNV. In the absence of lycorine, the mutant and WT
replicons yielded equal levels of luciferase activities at 2, 4, and 6 h
p.t.; in contrast, themutant replicon exhibited luciferase signals 2.5-, 2-,
and 1.4-fold higher than the WT replicon at 24, 30, and 48 h p.t.,
respectively (Fig. 8A). These results demonstrate that the 2K peptide
mutation does not affect viral translation, but it instead enhances RNA
synthesis, especially at the early replication stage. In the presence of
inhibitor (1.5 μM), the luciferase signals from the WT and mutant
replicons were reduced. The reporting signals at 2, 4, and 6 h p.t. were
slightly suppressed (b30%) for both replicons; however, the luciferase
activities at 24, 30, and 48 h p.t. from the WT replicon were more
dramatically suppressed by the compound than were the activitiesfrom the mutant replicon. These results again demonstrate that the
single-amino acid change in the 2K peptide is responsible for lycorine
resistance.
To further examine the effect of the G6871A mutation in the 2K
peptide on viral replication, we compared the growth kinetics of the
WT and mutant viruses. Vero and mosquito C6/36 cells were each
infected with WT or mutant virus (0.05 MOI) and were then
monitored for viral yields. In Vero cells, the mutant virus produced
titers 4.2- and 2.7-fold higher than those of the WT virus at 24 and
36 h p.i., respectively; the difference in viral titer was reduced to b1.4-
fold after 48 h p.i. (Fig. 8B). In C6/36 cells, the mutant virus generated
titers 2.8-to 4.4-fold higher than those of the WT virus at all tested
time points. For both Vero and C6/36 cells, similar titers of theWTand
mutant viruses were detected at 12 h p.i.; these low viral titers were
most likely derived from the input viruses during inoculation, and are
not substantially composed of progeny viruses. These results, together
with the transient replicon data (Fig. 8A), strongly indicate that the 2K
peptide mutation enhances viral replication. It should be noted that
the replication enhancement was not evident when the plaque sizes
were compared between the WT and mutant viruses (Fig. 6B).
Fig. 7. Replication kinetics of WT and 2K-mutant viruses in the presence and absence of lycorine. Vero cells, in a 12-well plate, were infected with WNV (WT and G6871A MT) at an
MOI of 5, incubated at 4°C for 1 h, washed three times with PBS, and incubated at 37°C with medium containing 1.2-μM lycorine or with medium containing 1% DMSO. At 16, 24, 36,
and 48 h p.i., viral titers in supernatants were determined by plaque assays (A). The infected cells werewashed twicewith PBS, lysed with 250 μl of lysis buffer, and frozen at-80°C. The
cell lysates (10 μl) were analyzed by western blotting (B). Four monoclonal antibodies against NS1 (1:1000 dilution; purchased from Sigma), NS3 (1:4000 dilution; in-house
generated), NS5 (1:4000 dilution; in-house generated), or β-actin (1:1000 dilution; purchased from Chemicon) were mixed and used as primary antibodies. Horse radish peroxidase
(HRP)-labeled anti-mouse IgG (1:4000 dilution) was used as a secondary antibody. β-actin was used as a loading control. One representative of two experiments is shown.
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We initiated chemistry studies by synthesizing seven lycorine
analogues (Table 1). The analogues were each examined for cyto-
toxicity and antiviral activity. Three regions of the parental lycorine
compoundweremodiﬁed. (i) One or twohydroxyl groups at the C1 and
C2 positions of lycorine were substituted with other chemical groups.
All seven analogues that contained these modiﬁcations showed CC50
values higher than the value for parental lycorine. Among them,
compound 1200, in which the hydroxyl group at the C1-position is
acetylated and the C2 hydroxyl group is oxidized to form a carbonyl
group, slightly increased the potency (EC50= 0.19 μM), while
signiﬁcantly reducing cytotoxicity (CC50N300 μM, the highest tested
concentration). As expected, the G6871Amutant virus was resistant to
compound 1200 (data not shown). (ii) The pyrrolidine ring of lycorine
was opened (compounds1193 and 1194). (iii) C7 of lycorine was
oxidized to a carbonyl group (compound 1197). Compounds from (ii)
and (iii) modiﬁcations had lower antiviral potencies. These results
clearly indicate that modiﬁcations at the two hydroxyl groups of
lycorine could be used to improve the antiviral proﬁle.
Discussion
A number of approaches have been reported for development of
ﬂavivirus antiviral agents (Shi, in press). The goals of this studywere to
establish the anti-ﬂavivirus activity of lycorine and to analyze
lycorine-resistant ﬂavivirus in cell culture. Previous studies showed
that lycorine inhibits poliovirus (Ieven et al., 1982), SARS-CoV (Li et al.,
2005), herpes simplex virus (Renard-Nozaki et al., 1989), and vaccinia
virus (Zhou et al., 2003). The current study has extended the antiviral
spectrum to ﬂaviviruses. In addition, we showed that lycorine does not
inhibit an alphavirus, WEEV, and a rhabdovirus, VSV, (Fig. 3). The latterresults, together with ﬁndings of an early study showing that lycorine
does not inhibit HIV-1 at a noncytotoxic concentration (Szlavik et al.,
2004), indicate the selectivity of the antiviral spectrum of the
compound. As a proof-of-principle, we showed that modiﬁcations of
the lycorine compound, especially at the two hydroxyl groups, could
dramatically reduce its cytotoxicity, while improve its potency (Table 1).
The results suggest that lycorine represents one class of inhibitor that
could potentially be developed for ﬂavivirus therapeutics.
Three WNV luciferase-reporting replicon-based assays were used
to dissect the inhibitory step(s) of lycorine. First, a VLP-infection-
based assay allowed identiﬁcation of inhibitors of viral entry and
replication (Fig. 1C). Second, use of Replicon-containing cell lines
allowed screening for inhibitors of viral replication (Fig. 4A). Third, a
transient replicon assay allowed differentiation between inhibitors of
translation and inhibitors of RNA synthesis (Fig. 4B). Analysis of the
compound in the above systems indicated that whereas lycorine
only weakly reduces viral translation (b30%, as indicated by
luciferase activity), it signiﬁcantly suppresses RNA synthesis (N99%,
as indicated by luciferase activity). The reduction of RNA synthesis
could be caused by the compound-mediated suppression of viral
translation. Alternatively, lycorine could suppress both translation
and RNA synthesis, leading to the dramatic reduction of RNA
synthesis. To differentiate between the above two possibilities, we
performed a time-of-addition experiment. The results showed that
lycorine gradually declined its anti-WNV activity, when the time of
addition was varied from 0 to 10 h p.i.; the compound completely
lost the inhibitory activity when added at N10 p.i. (Fig. 4C). A single
round of ﬂavivirus infection is about 12 h in duration, with viral
translation peaking around 2–6 h p.i. and RNA synthesis peaking
around 7–12 h p.i. (Chambers et al., 1990; Puig-Basagoiti et al., 2005).
If lycorine only inhibited the step of translation, it would have
completely lost its antiviral activity when added at a time point
Fig. 8. Enhancement of viral replication through mutation of the 2K peptide. (A)
Resistance and replication analyses using WNV replicon. The effect of the G6871A
mutation in the 2K peptide on resistance to lycorine was quantiﬁed using a transient
replicon (Rluc2A-Rep) assay. Equal amounts (10 μg) of WT and G6871A mutant
replicon RNAs were electroporated into BHK-21 cells. The transfected cells were
immediately treated with lycorine (1.5 μM) or without lycorine (1% DMSO as controls).
Luciferase activities were measured at the indicated time points post-transfection.
Average results from three independent experiments are presented. (B) Growth
kinetics of WT and 2K peptide G6871A mutant viruses. Vero and C6/36 cells were
infected with the WT and the 2K peptide mutant viruses at an MOI of 0.05. After 1-h
incubation, the cells were washed three times with PBS and the medium was
replenished. Viral titers in culture ﬂuids were quantiﬁed at the indicated time points
using plaque assays.
Table 1
Antiviral activities of lycorine analogues
aCC50 values were derived from Vero cells using an MTT assay.
bEC50 values were derived from viral titer reduction assays. Vero cells were infected with
WNV (0.1 MOI) in the presence of various concentrations of each compound. Viral titers at
42 h p.i. were determined by plaque assays, as described in Materials and methods.
249G. Zou et al. / Virology 384 (2009) 242–252earlier than 10 h p.i. (i.e., at 6 h p.i.). Therefore, the time-of-addition
results clearly indicate that the compound inhibits a step beyond
viral translation. These data, together with the identiﬁcation of the
resistance determinant in the 2K peptide (Fig. 6), led us to conclude
that lycorine suppresses WNV mainly through suppression of viral
RNA synthesis.
Our data are in contrast to poliovirus results, which indicated that
∼90% of viral translation was suppressed by 10 μg/ml (equivalent to
31 μM) lycorine (Ieven et al., 1982). Since the cytotoxicity of lycorine at
31 μMwas not shown in the poliovirus study, experiments are needed
to exclude the possibility that the strong inhibition of viral translationwas due to compound-mediated cytotoxicity. We performed the
mode-of-action analysis at b1.5 μM of lycorine, a concentration that
allowed N90% cell viability. In our system, lycorine at 31 μM decreased
the viability of Vero cells by ∼50% (Fig. 2A).
Two approaches were taken to identify potential the viral target(s)
of lycorine. The ﬁrst approach was to test the compound in
biochemical enzyme assays using recombinant protease (with
NS2B), NTPase, RdRp, and MTase proteins. None of the enzyme
activities were suppressed by lycorine. The second approach was to
select compound-resistant WNV. We selected resistant WNVs in cell
culture. Engineering of the mutations (recovered from the resistant
viruses) into an infectious clone (Fig. 6) and a replicon (Fig. 8A) of
WNV allowed us tomap the resistance determinant to a single amino-
acid change (Val9Met) in the 2K peptide. It should be noted that the
resistance results do not necessarily indicate that the 2K peptide is the
direct target for lycorine. The 2K peptide mutation could exert its
resistance phenotype through enhancement of viral replication so
250 G. Zou et al. / Virology 384 (2009) 242–252that, in the presence of inhibitor, viral replication could still be
sustained at a level sufﬁcient to generate virus. The latter scenario is
supported by the observations that the 2K peptidemutation enhanced
RNA synthesis of WNV replicon as well as the growth kinetics of WNV
in Vero and C6/36 cells (Fig. 8). However, it should be pointed out that
the 2K mutation-mediated enhancement of viral replication only
partially contributes to the lycorine resistance. The latter conclusion
was supported by the results that the 2K mutation increased
replication by only 2 to 4-fold in the absence of lycorine (Fig. 8B),
whereas the same mutation increased replication by N100-fold in the
presence of the inhibitor (Fig. 7A).
Howdoes the 2K peptidemutation enhanceWNVRNA replication?
Flavivirus 2K peptide spans the ER membrane with its N- and C-
terminal tails on the cytoplasmic and ER lumen sides, respectively
(Miller et al., 2007). The cleavage at the 2K-NS4B junction by host
signalase requires a prior cleavage at the NS4A-2K junction by viral
NS2B/NS3 protease (Lin et al., 1993). The regulated cleavages at the
NS4A-2K-NS4B sites play a role in rearranging cytoplasmicmembranes
(Miller et al., 2007; Roosendaal et al., 2006). The exact function of the
2K peptide in induction of membrane arrangement may differ among
ﬂaviviruses. In KUNV, individual expression of NS4A-2K resulted in
membrane rearrangements that most resembling virus-induced
structures, while removal of the 2K domain led to a less profound
membrane rearrangement (Roosendaal et al., 2006). In contrast,
expression of DENV-2 NS4A without 2K peptide resulted in altered
membranes resembling virus-induced structures, whereas expression
of NS4A-2K did not induce comparable membrane arrangement
(Miller et al., 2007). Since the rearrangedmembranes form the scaffold
for the viral replication complex, the Val9Met mutation may affect the
2K peptide-mediated membrane alterations, leading to an increase in
RNA replication.
Alternatively, since the cleavages of NS4A-2K-4B intermediate are
critical for the NS4A- and NS4B-mediated inhibition of interferon
signaling (Munoz-Jordan et al., 2005), the Val9Met mutation in the 2K
peptide may affect the processing of the NS4A-2K-4B polyprotein,
resulting in a more efﬁcient defense against the host immune
response. The weakened interferon response allowed the virus to
replicate to a higher level. This hypothesis is supported by our
observations that the same 2K peptide mutation was recovered from
the WNV that was able to perform superinfections (Zhang and Shi,
unpublished data). In the later study, we found that the 2K peptide
mutant virus showed improved capability to replicate in cells that
contain persistently replicating replicon of WNV. One caveat to this
hypothesis is that our lycorine resistance study was performed in Vero
cells, in which the interferon gene has been deleted (Mosca and Pitha,
1986). More experiments are required to dissect the molecular
mechanism of the 2K peptide that is operative in ﬂavivirus replication
or in evasion of the host immune response.
Materials and methods
Cells and viruses
Baby hamster kidney cells (BHK-21) and African green monkey
kidney cells (Vero) were cultured in Dulbecco modiﬁed Eagle medium
(DMEM) with 10% fetal bovine serum in 5% CO2 at 37°C. Aedes
albopictus C6/36 cells were grown in Eagle's minimal essential
medium (EMEM) with 10% FBS and 1% non-essential amino acid at
28°C. A reporting Vero cell line containing a persistently replicating
WNV or DENV-1 replicon (Rluc-Neo-Rep; Fig. 4A) was cultured in
DMEM with 10% FBS and 1 mg/ml of G418. WNV was derived from a
full-length infectious cDNA clone of an epidemic strain 3356 (Shi et al.,
2002a, 2002b). YFV (17D vaccine strain), DENV-2 (New Guinea C
strain), WEEV (strain Cova 746), and VSV (New Jersey serotype) were
used for antiviral assays, as described previously (Puig-Basagoiti et al.,
2006).Lycorine and analogues
Lycorine was purchased from BIOMOL Research Laboratories Inc. A
panel of seven lycorine analogues (Table 1) was synthesized based on
previous methodology: compounds 1180 (Lee et al., 2007), 1181
(Nakagawa, Uyeo, and Yajima, 1956), 1193 (Lee et al., 2007), 1194 (Lee
et al., 2007), 1197 (Shu et al., 2002), and 1200 (Nakagawa et al., 1956).
The method for synthesis of compound 1198 will be described
elsewhere. The structure and purity (N95%) of each compound were
established by nuclear magnetic resonance. All compounds were
dissolved in dimethyl sulfoxide (DMSO), and were tested at 1% DMSO
ﬁnal concentration. Mock-treated reactions were incubated with 1%
DMSO without lycorine or any of its analogues.
VLP infection assay
VLPs of WNV and DENV-1 were prepared by trans-supply of viral
structural proteins to replicon RNAs. Each replicon contains a Renilla
luciferase (Rluc) and foot-and-mouth disease virus 2A sequence in
the position where the viral structural genes (CprME) were deleted
(Rluc2A-Rep; Fig. 1B). The construction and characterization of the
WNV and DENV-1 Rluc2A-Rep were reported previously (Lo et al.,
2003; Puig-Basagoiti et al., 2006). The structural genes of each virus
were cloned into an SFV expression vector (Invitrogen) (Liljestrom
and Garoff, 1991) at a unique Bam HI site, resulting in SFV-CprME
(Fig. 1B). A Kozak sequence and a stop codon were engineered at the
5′ and 3′ ends of the CprME fragment, respectively. A double-
transfection protocol was used to generate the VLPs (Khromykh
et al., 1998; Puig-Basagoiti et al., 2005). Brieﬂy, BHK-21 cells (8×106)
were ﬁrst electroporated with 10 μg of Rluc2A-Rep RNA in a 0.4-cm
cuvette with the GenePulser apparatus (Bio-Rad) using settings of
0.85 kV and 25 μF, pulsing three times at 3-sec intervals. The
transfected cells were resuspended in DMEM with 10% FBS and
incubated at 37°C with 5% CO2 for 24 h. The replicon-transfected
cells were then electroporated with 10 μg of SFV-CprME RNA of the
corresponding virus, at the settings identical to those used for the
ﬁrst transfection. At 24 h after the second transfection, culture
supernatants were collected and centrifuged to remove cellular
debris. The VLPs in the supernatants were aliquoted and stored at-
80°C. The titers of VLPs (in focus-forming units [FFU]/ml) were
estimated by infection of Vero cells in a four-chamber Lab-Tek
Chamber Slide (Nalge Nunc International) with serial dilutions of the
culture ﬂuid, followed by counting of immunoﬂuorescence assay
(IFA)-positive cell foci at 18 and 24 h p.i. for WNV and DENV-1,
respectively. For IFA, immune mouse ascites ﬂuid of WNV or DENV-1
(American Type Culture Collection) and goat anti-mouse immuno-
globulin G conjugated with Texas Red were used as primary and
secondary antibodies, respectively.
For VLP-based antiviral assays, a monolayer of naive Vero cells
(2×104 cells per well in 96-well plate) was infected at 1 FFU/cell for
WNV VLP, and at 0.01 FFU/cell for DENV-1 VLP. Lycorine was
immediately added to the VLP-infected cells. At 24 h p.i., the cells
were washed twice with cold PBS, lysed in 20 μl of 1× Renilla
luciferase lysis buffer for 20 min, and assayed for luciferase activities
using a Renilla luciferase assay kit (Promega). The luciferase signals
were measured with a Veritas Microplate Luminometer (Promega).
Average results of three or more independent experiments are
presented here.
Reporting replicon cell line assay
Vero cells containing persistently replicating replicons of WNV (Lo
et al., 2003) or DENV-1 (Puig-Basagoiti et al., 2006) were constructed
previously. Each replicon contained two reporter genes: a Renilla
luciferase (Rluc) and a neomycin phosphotransferase gene (Neo),
resulting in Rluc-Neo-Rep (Fig. 4A). For antiviral assays, Rluc-Neo-Rep-
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plates in DMEMwith 10% FBSwithout G418. Lycorinewas added to the
medium at 24 h post-seeding. After 24 or 48 h of lycorine-treatment,
the cells were lysed and assayed for luciferase activities as described
above.
Transient replicon assay
A transient replicon assay was used to quantify compound-
mediated inhibition of viral translation and suppression of RNA
synthesis (Deas et al., 2005). Brieﬂy, 10 μg of Rluc2A-Rep RNA of WNV
or DENV-1 (Fig. 4B) was electroporated into BHK-21 cells (8×106) as
described above. The transfected cells were suspended in 25 ml of
DMEM with 10% FBS. Cell suspension (1 ml) was seeded into 12-well
plates, immediately treated with lycorine, and assayed for luciferase
activities at 2, 4, and 6 h p.t. (representing viral translation), and at 24,
30, and 48 h p.t. (representing RNA synthesis). For quantiﬁcation of
compound-mediated inhibition, relative luciferase activities were
presented, with the luciferase activity derived from the mock-treated
cells set as 100%.
Viral titer reduction assay and cytotoxicity assay
Viral titer reduction assays were performed to examine the
antiviral activities of lycorine and its analogues in WNV, DENV-2,
YFV, WEEV and VSV. Approximately 6×105 Vero cells per well were
seeded in a 12-well plate. After incubation for 24 h, the cells were
infected with individual virus (0.1 MOI) and treated immediately with
one of the compounds at the indicated concentration. For WNV,
DENV-2, YFV, andWEEV, samples of culture mediumwere collected at
42 h post-infection. For VSV, culture medium was collected at 16 h
post-infection. All collected samples were stored at −80°C, and viral
titers were determined by plaque assays on Vero cells. A double-
overlayer protocol was followed for plaque assays (Puig-Basagoiti
et al., 2006). All assays were performed in triplicate. Cytotoxicity of
each compound was examined using a cell proliferation-based MTT
assay (American Type Culture Collection) as described previously
(Puig-Basagoiti et al., 2006).
Generation and sequencing of WNV resistant to lycorine
Three independent lineages of lycorine-resistant WNV were
generated by passaging of the WT WNV (derived from an infectious
cDNA clone) on Vero cells, with increasing concentrations of lycorine.
For theﬁrst six passages, Vero cells in 12-well plateswere infectedwith
WNV (derived each time from the previous passage) at anMOI of 0.1 in
the presence of 0.8 μM lycorine or 1% DMSO (as a negative control).
Passages 7 to 12 were selected with 1.2 μM lycorine. For each passage,
viral supernatants were harvested at 42 h p.i.; viral titers were
quantiﬁed by plaque assays; viruseswere analyzed in resistance assays
to monitor the improvement of resistance, through comparison of the
viral titers from the lycorine-treated infections with the viral titers
from the mock-treated infections. The selections were terminated at
passage 12, when no further improvement of the resistance was
observed (see details in Results).
Lycorine-resistant WNVs from passage 12 were subjected to
genome-length sequencing for identiﬁcation of accumulated muta-
tion(s). Virion RNAs were extracted from culture supernatants using
RNeasy kits (QIAGEN). Viral RNAs were ampliﬁed by RT-PCR using
SuperScript III one-step RT-PCR kits (Invitrogen). The PCR products
were gel-puriﬁed and subjected to DNA sequencing. Sequences of
the 5′- and 3′-terminal nucleotides of the viral genomes were
determined by rapid ampliﬁcation of cDNA ends (RACE). The 5′RACE
was performed using the FirstChoice RLM-RACE kit (Ambion). The 3′
RACE was performed as previously described (Tilgner and Shi,
2004).Construction of cDNA plasmids of WNV containing various mutations
WNV genome-length cDNA clones with speciﬁc mutations were
constructed by using amodiﬁed pFLWNV (Shi et al., 2002a, 2002b) and
two shuttle vectors. Shuttle vector A was constructed by engineering
the Bam HI-Sph I fragment from the pFLWNV (representing the
upstream end of the T7 promoter [for RNA transcription of genome-
lengthRNA] to nucleotide position 3627of theWNVgenome;GenBank
no. AF404756) into the pACYC177 vector containing amodiﬁed cloning
cassette (Zhou et al., 2007). A QuikChange II XL site-directed
mutagenesis Kit (Stratagene) was used to engineer the mutations in
the E gene into the shuttle vector A. The mutated DNA fragment was
cut-and-pasted back into the pFLWNV clone at the Bam HI and Stu I
sites (nucleotide position 2591). Shuttle vector B was constructed by
engineering Kpn I-Xba I fragment (representing nucleotide 5341
through the 3′ end of the genome) into a pcDNA3.1(+) vector. The
G6871A mutation was engineered into the shuttle vector B using the
QuikChange II XL site-directed mutagenesis Kit. The mutated DNA
fragment was pasted back into the pFLWNV clone and into the cDNA
clone of WNV Rluc2A replicon at the Bsi WI and Spe I sites (nucleotide
positions 5780 to 8022). All constructs were veriﬁed by DNA
sequencing.
RNA transcription and transfection
Both genome-length RNA and replicon RNA were in vitro
transcribed from corresponding cDNA plasmids that were linearized
with XbaI. A T7 mMessage mMachine kit (Ambion) was used for RNA
synthesis described before (Shi et al., 2002a). Both replicon and
genome-length RNAs were electroporated into BHK-21 cells as
described above. For transfection of genome-length RNA, culture
ﬂuids were collected every 24 h until apparent cytopathic effect was
observed (day 4 to day 5 post-transfection). The viruses in the
supernatants were aliquoted and stored at −80°C.
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